Skip to main content
. 2021 Aug 9;8(6):e1059. doi: 10.1212/NXI.0000000000001059

Table 3.

Competing Risk Regression Analyses for RAW and PIRA on 224 Patients With No Evident Disease Activity After the First 2 Years of Treatment

graphic file with name NEURIMMINFL2021039128T3.jpg